Strategic Upgrade Through Divestiture: VB Spine Emerges as a Focused Spine Solutions Leader Following Stryker Asset Acquisitions

　　【Pharmaceutical Network Enterprise NewsOn January 9, VB Spine announced the successful acquisition of Stryker's spinal implant manufacturing plant located in Cestas, France. The plant holds a core position in VB Spine’s global manufacturing operations due to its advanced operational model and technical expertise. This acquisition will provide VB Spine with state-of-the-art production facilities, enabling the integration of high-quality resources, improving production efficiency and product quality, and strengthening its competitiveness in the global spinal implant market.
 

It is reported that this acquisition stemmed from a collaboration between Stryker and Viscogliosi Brothers in 2025, when Stryker sold its U.S. spinal implant business to the investment firm. On January 28 last year, Stryker announced it had reached an agreement to sell its U.S. spinal implant business to Viscogliosi Brothers, with the new company named VB Spine. Under the agreement, VB Spine will serve as a strategic partner of Stryker, gaining exclusive rights to use the Mako Spine system and the Copilot assisted system for VB Spine’s implants in spinal surgeries.
 

At the same time, the agreement also includes a legally binding offer to plan the acquisition of Stryker's spinal implant business in France. In addition, Stryker's spinal implant business in other international markets is also expected to be sold, provided that all legal and regulatory requirements are met, including any necessary consultations.
 

Stryker's spinal implant business mainly focuses on the treatment of spinal diseases and surgical solutions, and the sale of this business is part of its strategic adjustment. Compared with "selling," in recent years, the company has been more focused on a strategy of rapidly integrating new technologies and expanding its global market share through mergers and acquisitions.
 

On January 6, 2025, Stryker announced that it had reached a definitive agreement to acquire all outstanding and circulating common shares of Inari Medical, Inc. for $80 per share in cash, with a total equity value of approximately $4.9 billion (equivalent to nearly 36 billion RMB) on a fully diluted basis.
 

Inari is a leading company in the field of venous thromboembolism (VTE), with an innovative product portfolio that highly complements Stryker's neurovascular business, including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
 

In addition, in 2024, Stryker completed 7 acquisitions, covering multiple cutting-edge fields. These include the acquisition of care.ai, which focuses on medical artificial intelligence, to enhance smart ward and information technology product capabilities; the acquisition of Artelon to improve its soft tissue fixation and sports medicine product lines; the acquisition of Cerus Endovascular to further expand in the interventional treatment field; and a strategic cooperation with C&D Zhi Xin to deepen the distribution network in the Chinese market.
 

Overall, Stryker's divestiture of its spine business is a typical "sacrificing a pawn to save the king" strategy. It marks the company's accelerated transformation from a diversified medical device manufacturer to one focused on "RobotA global medical technology enterprise with "technology and digital solutions" at its core. In the future, its development will continue to focus on "strengthening the core, intelligent upgrading, and acquisition expansion."
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.